GlucoTrack, Inc. heads into the week with one of the most extreme short-interest profiles in the small-cap health care universe — a stock priced at $0.73 and falling, with bears commanding a position that dwarfs the available float.
Short interest has exploded over the past month. From under 4% of free float in late March, SI climbed to 42.5% by May 5 — a gain of more than 1,200% on the week ending May 4, and a 156% rise over the month. The peak, hit April 30 at just under 70% of the float, has eased slightly, but the current reading of 42.5% still leaves shorts owning nearly half of every freely traded share. This is not a stock with a marginal bear tilt — it is one where short positioning has become structurally dominant.
The borrow market confirms the aggression. Cost to borrow has climbed to 556% annualised, up 45% on the week and more than twelve times the level seen in late March when CTB was just 40%. That kind of trajectory tells a clear story: demand for borrows has surged, and lenders are pricing scarcity accordingly. Availability has tightened in parallel — the borrow pool is not yet fully exhausted, but with CTB at these levels, new shorts are paying a severe carry penalty to maintain positions. The ORTEX short score reflects this — at 80.8 out of 100, it sits well into the top decile of short conviction signals, and has held above 80 for the entire past week.
The earnings history adds important context to the bear thesis. Every recent event-day move for GCTK has been negative. The April 14 event produced a 15% drop on the day. A March 30 filing sent the stock down 34% in a single session. The March 12 earnings release cost another 10% on day one, extending to an 18% loss over five days. The one outlier is a November 2025 event that saw a 37% five-day recovery — but that appears isolated against a pattern of consistent post-event selling. There is no next earnings date flagged at present.
Institutional ownership offers little cushion. The top holder is Armistice Capital with just over 5% of shares, followed by Ikarian Capital and a private trust each holding around 2.4%. Total disclosed institutional interest is thin across only 15 holders. Insider data is stale — the last logged trades date to April 2024 and carry low significance scores, so that picture tells us nothing about recent conviction.
The price itself reflects the pressure. GCTK closed at $0.73 on May 5, down 13% over the past month and off nearly 1% on the day. Nasdaq-listed peers like GUTS and OBIO held steadier on the week, gaining 6% and 3% respectively, underscoring that GCTK's decline is specific rather than sector-wide. The contrast is notable: while the broader small-cap health care names drift sideways, GCTK has a short base large enough to dictate price action on its own terms.
What to watch next is straightforward: whether short interest continues unwinding from its April 30 peak of 70% FF — further covering would reduce the borrow burden and potentially stabilise the price — or whether a renewed catalyst reignites bear positioning and pushes CTB toward and beyond the 52-week high of 99.8% availability utilisation seen earlier in the year.
See the live data behind this article on ORTEX.
Open GCTK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
